Management of osteoporosis in men on androgen deprivation therapy

Maturitas

Volumn 68, Issue 2, 2011, Pages 143-147

  Adler, Robert A ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Androgen deprivation therapy; Bisphosphonates; Denosumab; Fracture; Osteoporosis; Prostate cancer; SERMs

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CITRATE CALCIUM; DENOSUMAB; PAMIDRONIC ACID; PLACEBO; RALOXIFENE; RISEDRONIC ACID; TOREMIFENE; VITAMIN D; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE DENSITY; BONE METASTASIS; CANCER LOCALIZATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISEASE PREDISPOSITION; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; FEMUR FRACTURE; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; HUMAN; JAW OSTEONECROSIS; MEDICAL EXPERT; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PROPHYLAXIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

EID: 78651390342     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2010.11.003     Document Type: Review

References (41)

1. V.B. Shaninian, Y.F. Kuo, J.L. Freeman, and J.S. Goodwin Risk of fracture after androgen deprivation therapy for prostate cancer N Engl J Med 352 2005 154 164
2. H. Liu, N.M. Paige, and C.L. Goldzweig Screening for osteoporosis in men: a systematic review for an American college of physicians guideline Ann Intern Med 148 2008 685 701
3. S. Levis, A. Gomez, and C. Jimenez Vitamin D deficiency and seasonal variation in an adult South Florida population J Clin Endocrinol Metab 90 2005 1557 1562
4. N. Binkley, R. Novotny, and D. Krueger Low vitamin D status despite abundant sun exposure J Clin Endocrinol Metab 92 2007 2130 2135
5. M. Kumari, S.E. Judd, and V. Tangpricha Vitamin D status in United States war veterans Endocr Pract 14 2008 127 128
6. B. Dawson-Hughes, A. Mithal, and J.P. Bonjour IOF position statement: vitamin D recommendations for older adults Osteoporosis Int 21 2010 1151 1154
7. National Osteoporosis Foundation Clinician's guide to prevention and treatment of osteoporosis 2008
8. M.J. Bolland, A. Avenell, and J.A. Baron Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis BMJ 341 2010 c3691
9. J.R. Lewis, J. Calver, K. Zhu, L. Flicker, and R.L. Prince Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RXT and a 4.5-year follow-up J Bone Miner Res 2010 [published online July 7]
10. L. Wang, J.E. Manson, Y. Song, and H.D. Sesso Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events Ann Intern Med 152 2010 315 323
11. C.S. Ryan, V.I. Petkov, and R.A. Adler Osteoporosis in men: the value of laboratory testing Osteoporos Int 2010 [published online October 9]
12. R.K. Chaganti, N. Parimi, and T. Lang Bone mineral density and prevalent osteoarthritis of the hip in older men for the Osteoporosis fractures in men (MrOS) study group Osteoporos Int 21 2010 1307 1316
13. D. Mittan, S. Lee, and E. Miller Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs J Clin Endocrinol Metab 87 2002 3656 3661
14. J.M. Bruder, J.Z. Ma, J.W. Basler, and M.D. Welch Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy Urology 67 2006 152 155
15. S.L. Greenspan Approach to the prostate cancer patient with bone disease J Clin Endocrinol Metab 93 2008 2 7
16. ® and its applications to clinical practice Bone 44 2009 734 743
17. P.J. Saylor, D.S. Kaufman, M.D. Michaelson, R.J. Lee, and M.R. Smith Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer J Urol 183 2010 2200 2205
18. R.A. Adler, F.W. Hastings, and V.I. Petkov Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX™ Osteoporos Int 21 2010 647 653
19. S.K. Sandhu, N.D. Ngyuyen, and J.R. Center Prognosis of fracture: evaluation of predictive accuracy of the FRAX™ algorithm and the Garvan nomogram Osteoporos Int 2009 [published online July 29]
20. F. Borgstrom, O. Johnell, B. Jonsson, N. Zethraeus, and S.S. Sen Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden Bone 34 2004 1064 1071
21. M.R. Smith, F.J. McGovern, and A.L. Zietman Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer N Engl J Med 345 2001 948 955
22. T.H. Diamond, J. Winters, and A. Smith The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study Cancer 92 2001 1444 1450
23. M.R. Smith, J. Eastham, and D.M. Gleason Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer J Urol 169 2003 2008 2012
24. J.M. Bruder, J.Z. Ma, N. Wing, J. Basler, and D. Katselnik Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy J Clin Densitom 9 2006 431 437
25. S.L. Greenspan, J.B. Nelson, D.L. Trump, and N.M. Resnick Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer Ann Intern Med 146 2007 416 424
26. M.D. Michaelson, H.L. Kaufman, and H. Lee Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer J Clin Oncol 25 2007 1038 1042
27. K. Ishizaka, T. Machida, and S. Kobayashi Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer Int J Urol 14 2007 1071 1075
28. Planas j, E. Trilla, and C. Raventos Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis BJU Int 104 2009 1637 1640
29. K. Izumi, A. Mizokami, and K. Sugimoto Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy Urology 73 2009 1342 1346
30. N. Bhoopalam, S.C. Campbell, and T. Moritz Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy J Urol 182 2009 2257 2264
31. P. Taxel, R. Dowsett, and L. Richter Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer BJU Int 2010 [published online April 30]
32. S.C. Campbell, N. Bhoopalam, and T.E. Moritz The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis Urology 75 2010 1138 1143
33. S. Khosla, D. Burr, and J. Cauley Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 22 2007 1479 1491
34. B. Abrahamsen Adverse effects of bisphosphonates Calcif Tissue Int 86 2010 421 435
35. E. Shane, D. Burr, and P.R. Ebeling Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 25 2010 2267 2294
36. M.R. Smith, A. Fallon, H. Lee, and J.S. Finkelstein Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial J Clin Endocrinol Metab 89 2004 3841 3846
37. M.R. Smith, R.A. Morton, and K.G. Barnette Toremifene to reduce fracture irsk in men receiving androgen deprivation therapy for prostate cancer J Urol 184 2010 1316 1321
38. M.R. Smith, B. Egerdie, and N.H. Toriz Denosumab in men receiving androgen-deprivation therapy for prostate cancer N Engl J Med 361 2009 745 755
39. J.H. Pickar, T. MacNeil, and K. Ohleth SERMs: progress and future perspectives Maturitas 67 2010 129 138
40. S.R. Cummings, J. San Martin, and M.R. McClung Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 2009 756 765
41. A.N. Tosteson, L.J. Melton 3rd, and B. Dawson-Hughes Cost-effective osteoporosis treatment thresholds: the United States perspective Osteoporos Int 19 2008 437 447